Category: OrbusNeichSyndicate content

OrbusNeich launches Combo stent pivotal trial in bid for Japanese approval

March 11, 2014 by Brad Perriello

OrbusNeich says it began enrolling patients in the Harmonee clinical trial of its Combo dual-therapy coronary stent, ahead of a planned bid for Japanese Shonin approval.

OrbusNeich launching its Japan stent trial

OrbusNeich Medical said it launched a clinical trial in the U.S. and Japan for its Combo dual-therapy coronary stent as it gears up to apply for Shonin approval in Japan.

Boston Scientific settles stent patent spat with OrbusNeich

September 17, 2013 by Brad Perriello

Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.

Boston Scientific settles stent patent spat with Orbusneich

Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments

August 14, 2013 by Arezu Sarvestani

Boston Scientific's latest legal updates provides some insight into a possible end in the long-running Guidant battles, a locking of arms in the Guidezilla disputes and minor progress in a few other litigations.

Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments

Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific legal update: Ups and downs in tussles with Iraq, OrbusNeich and the feds

May 29, 2013 by Arezu Sarvestani

Medical device titan Boston Scientific provides updates on some of its long-standing legal battles, including a mass-complaint from the Iraqi government, a dwindling whistleblower lawsuit over stent marketing and the never-ending patent spat with OrbusNeich.

Legal gavel

Boston Scientific (NYSE:BSX) is no stranger to the court room, and its latest quarterly release is a testament to the company's legal tenacity.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

OrbusNeich lands CE Mark for Combo dual-therapy stent

May 28, 2013 by Sony Salzman

OrbusNeich says its Combo dual-therapy stent is the 1st drug-eluting stent to win CE Mark approval in the European Union that combines traditional DES technology with the stimulation of healthy blood vessel growth.

OrbusNeich

OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific denies OrbusNeich accusations

May 21, 2013 by Brad Perriello

Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of stants whose importation is banned in Germany.

OrbusNeich: Boston Scientific lied about stents under German injunction

German court issues 2nd injunction against Boston Scientific in OrbusNeich stent patent spat

May 14, 2013 by Brad Perriello

A German court issues a 2nd injunction barring Boston Scientific from importing drug-eluting stents into that country.

German court issues 2nd injunction against Boston Scientific in OrbusNeich stent patent spat

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp